Nkarta (NKTX) Stock Overview
A clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NKTX Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Nkarta, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.11 |
| 52 Week High | US$3.81 |
| 52 Week Low | US$1.31 |
| Beta | 0.87 |
| 1 Month Change | -0.94% |
| 3 Month Change | 1.93% |
| 1 Year Change | -34.67% |
| 3 Year Change | -81.86% |
| 5 Year Change | -92.86% |
| Change since IPO | -95.60% |
Recent News & Updates
Is Nkarta (NASDAQ:NKTX) In A Good Position To Deliver On Growth Plans?
Nov 01
Nkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025
Jul 22Here's Why We're Watching Nkarta's (NASDAQ:NKTX) Cash Burn Situation
Jul 15Recent updates
Is Nkarta (NASDAQ:NKTX) In A Good Position To Deliver On Growth Plans?
Nov 01Nkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025
Jul 22Here's Why We're Watching Nkarta's (NASDAQ:NKTX) Cash Burn Situation
Jul 15Nkarta: Betting On The Turnaround
Mar 31Will Nkarta (NASDAQ:NKTX) Spend Its Cash Wisely?
Feb 27Nkarta, Inc.: Trying To Find Space In A Crowded Place
Jan 02Nkarta: Catalysts Ahead, But Competition In Cell Therapy Too (Rating Downgrade)
Oct 31We're Hopeful That Nkarta (NASDAQ:NKTX) Will Use Its Cash Wisely
Sep 10Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients
Aug 14Nkarta: A Look Into Q1 Results And Upcoming Catalysts
May 23Nkarta: Down 50% Since March With A Clinical Catalyst Ahead
Apr 27Nkarta: NK Cell Therapy Advancement On Two Fronts
Mar 25Nkarta: Possible Upside From H1 Update, If Positive
Jan 25Here's Why We're Watching Nkarta's (NASDAQ:NKTX) Cash Burn Situation
Jan 16We're Keeping An Eye On Nkarta's (NASDAQ:NKTX) Cash Burn Rate
Oct 04We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth
Jun 21We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth
Mar 06Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation
Nov 20Nkarta GAAP EPS of -$0.61
Aug 11We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate
Jun 09Nkarta: A Promising Natural Killer Cell Play
May 20We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth
Aug 23Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans
May 10We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate
Jan 25
Shareholder Returns
| NKTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.2% | 2.8% | -0.2% |
| 1Y | -34.7% | 4.0% | 20.3% |
Return vs Industry: NKTX underperformed the US Biotechs industry which returned 4% over the past year.
Return vs Market: NKTX underperformed the US Market which returned 20.3% over the past year.
Price Volatility
| NKTX volatility | |
|---|---|
| NKTX Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NKTX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NKTX's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 110 | Paul Hastings | www.nkartatx.com |
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company’s lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG.
Nkarta, Inc. Fundamentals Summary
| NKTX fundamental statistics | |
|---|---|
| Market cap | US$149.86m |
| Earnings (TTM) | -US$109.24m |
| Revenue (TTM) | n/a |
Is NKTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NKTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$109.24m |
| Earnings | -US$109.24m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.54 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NKTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/03 17:36 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nkarta, Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Maughan | Canaccord Genuity |
| Joshua Schimmer | Evercore ISI |
| Emily Bodnar | H.C. Wainwright & Co. |